Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Hip Osteoarthritis Pain Drug market report explains the definition, types, applications, major countries, and major players of the Hip Osteoarthritis Pain Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Hengrui Pharmaceutical
Mylan
Abiogen Pharma
Astellas Pharma
Abbott
Tide Pharmaceutical
Almatica Pharma
Pfizer
Novartis
TEVA
Sanofi
Daiichi Sankyo
Bayer
Horizon Pharma
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Iroko Pharmaceuticals
By Type:
Oral
Injection
External
By End-User:
Medical Care
Personal Care
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Hip Osteoarthritis Pain Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Hip Osteoarthritis Pain Drug Outlook to 2028- Original Forecasts
-
2.2 Hip Osteoarthritis Pain Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Hip Osteoarthritis Pain Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Hip Osteoarthritis Pain Drug Market- Recent Developments
-
6.1 Hip Osteoarthritis Pain Drug Market News and Developments
-
6.2 Hip Osteoarthritis Pain Drug Market Deals Landscape
7 Hip Osteoarthritis Pain Drug Raw Materials and Cost Structure Analysis
-
7.1 Hip Osteoarthritis Pain Drug Key Raw Materials
-
7.2 Hip Osteoarthritis Pain Drug Price Trend of Key Raw Materials
-
7.3 Hip Osteoarthritis Pain Drug Key Suppliers of Raw Materials
-
7.4 Hip Osteoarthritis Pain Drug Market Concentration Rate of Raw Materials
-
7.5 Hip Osteoarthritis Pain Drug Cost Structure Analysis
-
7.5.1 Hip Osteoarthritis Pain Drug Raw Materials Analysis
-
7.5.2 Hip Osteoarthritis Pain Drug Labor Cost Analysis
-
7.5.3 Hip Osteoarthritis Pain Drug Manufacturing Expenses Analysis
8 Global Hip Osteoarthritis Pain Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Hip Osteoarthritis Pain Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Hip Osteoarthritis Pain Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Hip Osteoarthritis Pain Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Hip Osteoarthritis Pain Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Oral Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Injection Consumption and Growth Rate (2017-2022)
-
9.1.3 Global External Consumption and Growth Rate (2017-2022)
-
9.2 Global Hip Osteoarthritis Pain Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Medical Care Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Personal Care Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Hip Osteoarthritis Pain Drug Market Analysis and Outlook till 2022
-
10.1 Global Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.2.2 Canada Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.2.3 Mexico Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.2 UK Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.3 Spain Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.4 Belgium Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.5 France Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.6 Italy Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.7 Denmark Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.8 Finland Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.9 Norway Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.10 Sweden Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.11 Poland Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.12 Russia Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.3.13 Turkey Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.2 Japan Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.3 India Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.4 South Korea Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.5 Pakistan Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.7 Indonesia Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.8 Thailand Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.9 Singapore Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.10 Malaysia Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.11 Philippines Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.4.12 Vietnam Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.2 Colombia Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.3 Chile Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.4 Argentina Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.5 Venezuela Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.6 Peru Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.5.8 Ecuador Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.6.2 Kuwait Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.6.3 Oman Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.6.4 Qatar Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.7.2 South Africa Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.7.3 Egypt Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.7.4 Algeria Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Hip Osteoarthritis Pain Drug Consumption (2017-2022)
-
10.8.2 New Zealand Hip Osteoarthritis Pain Drug Consumption (2017-2022)
11 Global Hip Osteoarthritis Pain Drug Competitive Analysis
-
11.1 Hengrui Pharmaceutical
-
11.1.1 Hengrui Pharmaceutical Company Details
-
11.1.2 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.1.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Mylan
-
11.2.1 Mylan Company Details
-
11.2.2 Mylan Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Mylan Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.2.4 Mylan Hip Osteoarthritis Pain Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Abiogen Pharma
-
11.3.1 Abiogen Pharma Company Details
-
11.3.2 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.3.4 Abiogen Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Astellas Pharma
-
11.4.1 Astellas Pharma Company Details
-
11.4.2 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Astellas Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.4.4 Astellas Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Abbott
-
11.5.1 Abbott Company Details
-
11.5.2 Abbott Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Abbott Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.5.4 Abbott Hip Osteoarthritis Pain Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Tide Pharmaceutical
-
11.6.1 Tide Pharmaceutical Company Details
-
11.6.2 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.6.4 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Almatica Pharma
-
11.7.1 Almatica Pharma Company Details
-
11.7.2 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Almatica Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.7.4 Almatica Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Pfizer
-
11.8.1 Pfizer Company Details
-
11.8.2 Pfizer Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Pfizer Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.8.4 Pfizer Hip Osteoarthritis Pain Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Novartis
-
11.9.1 Novartis Company Details
-
11.9.2 Novartis Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Novartis Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.9.4 Novartis Hip Osteoarthritis Pain Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 TEVA
-
11.10.1 TEVA Company Details
-
11.10.2 TEVA Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 TEVA Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.10.4 TEVA Hip Osteoarthritis Pain Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Sanofi
-
11.11.1 Sanofi Company Details
-
11.11.2 Sanofi Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Sanofi Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.11.4 Sanofi Hip Osteoarthritis Pain Drug Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Daiichi Sankyo
-
11.12.1 Daiichi Sankyo Company Details
-
11.12.2 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.12.4 Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Bayer
-
11.13.1 Bayer Company Details
-
11.13.2 Bayer Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Bayer Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.13.4 Bayer Hip Osteoarthritis Pain Drug Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Horizon Pharma
-
11.14.1 Horizon Pharma Company Details
-
11.14.2 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Horizon Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.14.4 Horizon Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Eli Lilly
-
11.15.1 Eli Lilly Company Details
-
11.15.2 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Eli Lilly Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.15.4 Eli Lilly Hip Osteoarthritis Pain Drug Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 GlaxoSmithKline
-
11.16.1 GlaxoSmithKline Company Details
-
11.16.2 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.16.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Johnson & Johnson
-
11.17.1 Johnson & Johnson Company Details
-
11.17.2 Johnson & Johnson Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Johnson & Johnson Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.17.4 Johnson & Johnson Hip Osteoarthritis Pain Drug Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 Iroko Pharmaceuticals
-
11.18.1 Iroko Pharmaceuticals Company Details
-
11.18.2 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
11.18.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Portfolio
-
11.18.5 Recent Research and Development Strategies
12 Global Hip Osteoarthritis Pain Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Injection Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global External Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Medical Care Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Personal Care Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Hip Osteoarthritis Pain Drug Market Analysis and Outlook to 2028
-
13.1 Global Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.5 France Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.3 India Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Hip Osteoarthritis Pain Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Hip Osteoarthritis Pain Drug
-
Figure of Hip Osteoarthritis Pain Drug Picture
-
Table Global Hip Osteoarthritis Pain Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Hip Osteoarthritis Pain Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Injection Consumption and Growth Rate (2017-2022)
-
Figure Global External Consumption and Growth Rate (2017-2022)
-
Figure Global Medical Care Consumption and Growth Rate (2017-2022)
-
Figure Global Personal Care Consumption and Growth Rate (2017-2022)
-
Figure Global Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Table North America Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure United States Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure Germany Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure France Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure China Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure India Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table South America Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure Brazil Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure Bahrain Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure Nigeria Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Hip Osteoarthritis Pain Drug Consumption by Country (2017-2022)
-
Figure Australia Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Hip Osteoarthritis Pain Drug Consumption and Growth Rate (2017-2022)
-
Table Hengrui Pharmaceutical Company Details
-
Table Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Mylan Company Details
-
Table Mylan Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mylan Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Mylan Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Abiogen Pharma Company Details
-
Table Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abiogen Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Abiogen Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Astellas Pharma Company Details
-
Table Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Astellas Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Abbott Company Details
-
Table Abbott Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Abbott Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Tide Pharmaceutical Company Details
-
Table Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tide Pharmaceutical Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Tide Pharmaceutical Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Almatica Pharma Company Details
-
Table Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Almatica Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Almatica Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Pfizer Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Novartis Hip Osteoarthritis Pain Drug Product Portfolio
-
Table TEVA Company Details
-
Table TEVA Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table TEVA Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table TEVA Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Sanofi Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Daiichi Sankyo Company Details
-
Table Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Daiichi Sankyo Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Bayer Company Details
-
Table Bayer Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Bayer Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Horizon Pharma Company Details
-
Table Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Horizon Pharma Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Horizon Pharma Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Eli Lilly Hip Osteoarthritis Pain Drug Product Portfolio
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table GlaxoSmithKline Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Johnson & Johnson Company Details
-
Table Johnson & Johnson Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Johnson & Johnson Hip Osteoarthritis Pain Drug Product Portfolio
-
Table Iroko Pharmaceuticals Company Details
-
Table Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Main Business and Markets Served
-
Table Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Product Portfolio
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global External Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Medical Care Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Personal Care Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Table North America Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure China Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Hip Osteoarthritis Pain Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Hip Osteoarthritis Pain Drug Consumption Forecast and Growth Rate (2022-2028)
-
